Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2019 1
2020 1
2021 4
2022 2
2023 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Results by year

Filters applied: Free full text. Clear all
Page 1
RUC-4: a novel alphaIIbbeta3 antagonist for prehospital therapy of myocardial infarction.
Li J, Vootukuri S, Shang Y, Negri A, Jiang JK, Nedelman M, Diacovo TG, Filizola M, Thomas CJ, Coller BS. Li J, et al. Arterioscler Thromb Vasc Biol. 2014 Oct;34(10):2321-9. doi: 10.1161/ATVBAHA.114.303724. Epub 2014 Aug 21. Arterioscler Thromb Vasc Biol. 2014. PMID: 25147334 Free PMC article.
Here, we report the properties of RUC-4 and the antiplatelet and antithrombotic effects of RUC-2 and RUC-4 in animal models. APPROACH AND RESULTS: RUC-4 was 20% more potent than RUC-2 in inhibiting human ADP-induced platelet aggregation a …
Here, we report the properties of RUC-4 and the antiplatelet and antithrombotic effects of RUC-2 and RUC-4 in an …
Preclinical Studies of RUC-4, a Novel Platelet alphaIIbbeta3 Antagonist, in Non-Human Primates and With Human Platelets.
Vootukuri S, Li J, Nedelman M, Thomas C, Jiang JK, Babayeva M, Coller BS. Vootukuri S, et al. J Clin Transl Sci. 2019 Jun;3(2-3):65-74. doi: 10.1017/cts.2019.382. Epub 2019 Jun 28. J Clin Transl Sci. 2019. PMID: 31544007 Free PMC article.
METHODS: We studied the: 1. pharmacokinetics (PK) of RUC-4 at 1.0, 1.93, and 3.86 mg/kg IV, IM, and SC in non-human primates (NHPs); 2. impact of aspirin on RUC-4 IC(50) in human platelet-rich plasma (PRP); 3. effect of different anticoagulants on the …
METHODS: We studied the: 1. pharmacokinetics (PK) of RUC-4 at 1.0, 1.93, and 3.86 mg/kg IV, IM, and SC in non-human primates ( …
Prehospital treatment with zalunfiban (RUC-4) in patients with ST- elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the CELEBRATE trial.
Rikken SAOF, Selvarajah A, Hermanides RS, Coller BS, Gibson CM, Granger CB, Lapostolle F, Postma S, van de Wetering H, van Vliet RCW, Montalescot G, Ten Berg JM, van 't Hof AWJ; CELEBRATE investigators. Rikken SAOF, et al. Am Heart J. 2023 Apr;258:119-128. doi: 10.1016/j.ahj.2022.12.015. Epub 2022 Dec 31. Am Heart J. 2023. PMID: 36592878 Free article. Clinical Trial.
First Human Use of RUC-4: A Nonactivating Second-Generation Small-Molecule Platelet Glycoprotein IIb/IIIa (Integrin alphaIIbbeta3) Inhibitor Designed for Subcutaneous Point-of-Care Treatment of ST-Segment-Elevation Myocardial Infarction.
Kereiakes DJ, Henry TD, DeMaria AN, Bentur O, Carlson M, Seng Yue C, Martin LH, Midkiff J, Mueller M, Meek T, Garza D, Gibson CM, Coller BS. Kereiakes DJ, et al. J Am Heart Assoc. 2020 Sep;9(17):e016552. doi: 10.1161/JAHA.120.016552. Epub 2020 Aug 26. J Am Heart Assoc. 2020. PMID: 32844723 Free PMC article. Clinical Trial.
Methods and Results Healthy volunteers and patients with stable coronary artery disease receiving aspirin received escalating doses of RUC-4 or placebo in a sentinel-dose, randomized, blinded fashion. Inhibition of platelet aggregation (IPA) to ADP (20 mumol/L), …
Methods and Results Healthy volunteers and patients with stable coronary artery disease receiving aspirin received escalating doses of RU …
Application of Auxiliary VerifyNow Point-of-Care Assays to Assess the Pharmacodynamics of RUC-4, a Novel alphaIIbbeta3 Receptor Antagonist.
Bentur OS, Li J, Jiang CS, Martin LH, Kereiakes DJ, Coller BS. Bentur OS, et al. TH Open. 2021 Sep 28;5(3):e449-e460. doi: 10.1055/s-0041-1732343. eCollection 2021 Jul. TH Open. 2021. PMID: 34604694 Free PMC article.
The results were correlated with both ADP (20 M)-induced LTA and flow cytometry measurement of receptor occupancy and data from individuals treated in vivo with RUC-4. Results RUC-4 inhibited all three VN assays, aspirin did not affect the assays, and …
The results were correlated with both ADP (20 M)-induced LTA and flow cytometry measurement of receptor occupancy and data from individuals …
Pharmacokinetics, pharmacodynamics, and tolerability of subcutaneous administration of a novel glycoprotein IIb/IIIa inhibitor, RUC-4, in patients with ST-segment elevation myocardial infarction.
Bor WL, Zheng KL, Tavenier AH, Gibson CM, Granger CB, Bentur O, Lobatto R, Postma S, Coller BS, van 't Hof AWJ, Ten Berg JM. Bor WL, et al. EuroIntervention. 2021 Aug 6;17(5):e401-e410. doi: 10.4244/EIJ-D-21-00287. EuroIntervention. 2021. PMID: 34031019 Free PMC article. Clinical Trial.
AIMS: The open-label, phase 2A, CEL-02 trial aimed to assess the pharmacodynamics (PD), pharmacokinetics (PK), and tolerability of RUC-4 in STEMI patients undergoing primary PCI (pPCI). METHODS: A total of 27 STEMI patients received a weight-adjusted subcutaneous in …
AIMS: The open-label, phase 2A, CEL-02 trial aimed to assess the pharmacodynamics (PD), pharmacokinetics (PK), and tolerability of RUC …
Rising like the phoenix?
Plow EF, Das M. Plow EF, et al. Arterioscler Thromb Vasc Biol. 2014 Oct;34(10):2182-3. doi: 10.1161/ATVBAHA.114.304486. Arterioscler Thromb Vasc Biol. 2014. PMID: 25231635 Free PMC article. No abstract available.
Rural-Urban Differences in Hospital and Patient-Reported Outcomes Following Total Hip Arthroplasty.
Lachance AD, Call C, Radford Z, Stoddard H, Sturgeon C, Babikian G, Rana A, McGrory BJ. Lachance AD, et al. Arthroplast Today. 2023 Sep 14;23:101190. doi: 10.1016/j.artd.2023.101190. eCollection 2023 Oct. Arthroplast Today. 2023. PMID: 37731592 Free PMC article.
Rurality was determined by rural-urban code (RUC) classifications by zip code with RUC codes 1-3 defined as urban and RUC 4-10 defined as rural. RESULTS: Patients from urban areas were more likely to visit the emergency department within 30 days postoperatively (P = …
Rurality was determined by rural-urban code (RUC) classifications by zip code with RUC codes 1-3 defined as urban and RUC 4-10 …
12 results